Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · Real-Time Price · USD

21.16

-3.44 (-13.98%)

At close: Dec 26, 2025, 4:00 PM EST

21.12

-0.04 (-0.19%)

After-hours: Dec 26, 2025, 7:58 PM EST

RGC Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2019 - 2020
Selling, General & Admin	2.82	3.78	4.69	5.11	0.94	Upgrade
Research & Development	0.95	0.95	1.58	2.51	0.44	Upgrade
Operating Expenses	3.77	4.74	6.27	7.62	1.38	Upgrade
Operating Income	-3.77	-4.74	-6.27	-7.62	-1.38	Upgrade
EBT Excluding Unusual Items	-3.77	-4.74	-6.27	-7.62	-1.38	Upgrade
Other Unusual Items	0.19	0.37	0.21	0.02	0.03	Upgrade
Pretax Income	-3.58	-4.36	-6.06	-7.59	-1.35	Upgrade
Earnings From Continuing Operations	-3.58	-4.36	-6.06	-7.59	-1.35	Upgrade
Minority Interest in Earnings	-	0.06	0.19	0.15	-	Upgrade
Net Income	-3.58	-4.3	-5.87	-7.45	-1.35	Upgrade
Net Income to Common	-3.58	-4.3	-5.87	-7.45	-1.35	Upgrade
Shares Outstanding (Basic)	494	494	494	487	380	Upgrade
Shares Outstanding (Diluted)	494	494	494	487	380	Upgrade
Shares Change (YoY)	-	-	1.62%	28.06%	-	Upgrade
EPS (Basic)	-0.01	-0.01	-0.01	-0.02	-0.00	Upgrade
EPS (Diluted)	-0.01	-0.01	-0.01	-0.02	-0.00	Upgrade
Free Cash Flow	-3.27	-4.01	-4.99	-6.05	-0.77	Upgrade
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.00	Upgrade
EBITDA	-3.69	-4.43	-5.98	-7.47	-1.35	Upgrade
D&A For EBITDA	0.08	0.31	0.29	0.15	0.03	Upgrade
EBIT	-3.77	-4.74	-6.27	-7.62	-1.38	Upgrade
Advertising Expenses	-	1	0.03	0.03	-	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q